Stage IVB cervical cancer
Conditions
Interventions
None listed
Sponsors
Japanese Gynecologic Oncology Group (JGOG) Japanese Radiation Oncology Study Group (JROSG)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Eighteen years of age or older at the time of initial examination. 2) Patients who has a histopathological diagnosis of cervical cancer and the histological type is either squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma. 3) Patients diagnosed with stage IVB (FIGO2018, Nissanpu 2020) at first presentation. Cases in which distant metastasis is limited to inguinal lymph node metastasis are excluded. 4) Patients who received chemotherapy with a treatment start date between January 1, 2016 and December 31, 2020. Chemotherapy in this section must have been administered as either (1) or (2) below. Radiotherapy is not required. (1) Patients must have received at least 4 courses of platinum doublet. (Bevacizumab is not required.) (2) Concurrent chemoradiotherapy with platinum drugs was administered.
Exclusion criteria
Exclusion criteria: 1) Patients who refused data registration. 2) Synchronous or metachronous (within 5 years) malignancies except for carcinoma in situ or mucosal tumors curatively treated with local therapy. 3) Patients who received surgery on the primary tumor during the course of treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival, rate of urinary tract and gastrointestinal tract adverse events (CTCAE Ver 5.0 Grade 3 or higher), rate of genital bleeding requiring blood transfusion | — |
Countries
Japan
Contacts
Public ContactKeisuke Tsuchida
Kanagawa Cancer Center Department of Radiation Oncology
Outcome results
None listed